Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
ConditionHypercholesterolemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFederico II University
About this trial
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
Eligibility criteria
Qualifiers
Patients under PCSK9 inhibitor treatment.
Disqualifiers
Age < 18 years o > 80 years;
Patients who refuse to participate and to sign informed consent.
Trial design
Treatments tested in this trial
- Repatha (evolocumab); Praluent (alirocumab)
Treatment groups
5,000 Participants
are divided into 1 treatment groupLocations
27Ospedali dell'Ovest Vicentino36071, Arzignano Italy
University of Bari Aldo Moro70121, Bari Italy
University of Campania Luigi Vanvitelli81100, Caserta Italy
University Magna Graecia of Catanzaro88100, Catanzaro Italy
Sponsors and collaborators
Federico II University
Lead sponsor
Source ClinicalTrials.gov